E2 transcription factor therapy (Enact)

N/A

Report date: 2025/03/19 20:00:56
NME

Base Information

Drug NameE2 transcription factor therapy (Enact)
Drug Alias NameHPV infection therapy (Enact)cervical cancer therapy (Enact)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNucleic acid metabolism modulators
TargetsUpdating
Therapy Area/IndicationsUterine Cervical NeoplasmsPapillomavirus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesEnact Pharma plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEnact Pharma plcCancer Research UK Manchester InstituteUniversity Of Bristol
Active IndicationsN/A
Inactive IndicationsUterine Cervical NeoplasmsPapillomavirus Infections

Other Information

ATC CodeN/A
Related LinksN/A